Iovance Biotherapeutics, Inc.
IOVA
$2.75
-$0.08-2.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.87% | 5.96% | 13.96% | 14.05% | 2.92% |
| Total Depreciation and Amortization | -5.32% | 4.83% | 2.61% | 9.66% | 1.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.68% | 18.02% | 0.82% | 98.81% | 23.43% |
| Change in Net Operating Assets | 53.58% | -185.19% | 65.60% | -18.93% | -373.80% |
| Cash from Operations | -41.47% | -24.29% | 40.09% | 19.50% | -45.62% |
| Capital Expenditure | -49.02% | -82.17% | -417.65% | 89.40% | -18.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -20,879.84% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -20.71% | 159.86% | -214.39% | 174.25% | 21.28% |
| Cash from Investing | -32.99% | 148.52% | -221.34% | 136.07% | -53.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,571.03% | -93.39% | -68.65% | -22.42% | 17,171.52% |
| Repurchase of Common Stock | -541.36% | 85.98% | -527.70% | 78.73% | -2,427.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,106.80% | -94.50% | -72.55% | -21.05% | 20,022.25% |
| Foreign Exchange rate Adjustments | 143.12% | -194.01% | 1,102.40% | 74.54% | -116.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 215.48% | 24.90% | -168.33% | 332.16% | 73.37% |